<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382157</url>
  </required_header>
  <id_info>
    <org_study_id>2019/842</org_study_id>
    <nct_id>NCT04382157</nct_id>
  </id_info>
  <brief_title>Magnesium Replacement and Hyperglycemia After Kidney Transplantation</brief_title>
  <official_title>Magnesium Replacement and Hyperglycemia After Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The insulin receptor is dependent on magnesium and hypomagnesemia is associated with
      increased insulin resistance and decreased insulin secretion and action. Recent data suggest
      that hypomagnesemia may play a role in development of type 2 diabetes. Kidney transplantation
      patients have low plasma magnesium levels, partly due to treatment with calcineurin
      inhibitors. However, the role of magnesium in the development of post-transplant diabetes
      mellitus (PTDM) is unclear.

      The present study addresses, whether hypomagnesemia is feasible to reverse by oral
      administration of magnesium.

      The investigators wish to investigate whether oral magnesium supplementation is sufficient to
      increase magnesium levels in kidney transplant recipients, and if supplementation improves
      glycemic parameters as measured by an oral glucose tolerance test (OGTT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnesium retension at loading test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Difference in magnesium retension at magnesium loading test between before and after oral treatment. Retension defined as percentage of magnesium retained from intravenous magnesium sulphate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose (mmol/L)</measure>
    <time_frame>Baseline (Before magnesium loading tests)</time_frame>
    <description>Change of fasting plasma glucose (mmol/L) between start and the end of supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin (mg/kg/min)</measure>
    <time_frame>2 hours oral glucose tolerance test</time_frame>
    <description>Change of insulin (mg/kg/min) in OGTT (after 2 hours) between start and the end of supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide (nmol/L)</measure>
    <time_frame>2 hours oral glucose tolerance test</time_frame>
    <description>Change of C-peptide (nmol/L) in OGTT (after 2 hours) between start and the end of supplementation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypomagnesemia</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Mablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mablet 360 mg</intervention_name>
    <description>Slow-released magnesium hydroxide</description>
    <arm_group_label>Mablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients more than one year after transplantation

          -  Hypomagnesemia (&lt; 0.7 mmol/L)

          -  Age â‰¥ 18 years and able to give written informed consent

        Exclusion Criteria:

          -  Current treatment with magnesium containing medication or supplements

          -  Current medical treatment for diabetes

          -  Conditions impairing magnesium absorption from the gastrointestinal tract (e.g. short
             bowel syndrome, chronic pancreatitis)

          -  Subjects with primary non-graft function and subjects with need of dialysis therapy &gt;2
             months or graftectomy at any time point after transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rasmus K Carlsen, MD</last_name>
    <phone>004723073544</phone>
    <email>r.k.carlsen@studmed.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trond Jenssen, Prof, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasmus Carlsen, MD</last_name>
      <phone>004723073544</phone>
      <email>r.k.carlsen@studmed.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Trond Jenssen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Oral glucose tolerance test</keyword>
  <keyword>Magnesium hydroxide</keyword>
  <keyword>hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

